Conclusion of a significant purchase order
The Management Board of Selvita S.A. with its registered office in Krakow (“Selvita” or “Company”) hereby announces that on December 9, 2022 the Company has received a purchase order with a total value of EUR 1.083.876,00 (PLN 5.084.679,10 converted at the average exchange rate published by the National Bank of Poland on December 12, 2022, EUR 1 = PLN 4,6912) under a framework agreement executed on June 20, 2018 (“Purchase Order”) between Selvita and one of the largest pharmaceutical companies in the world with its registered office in Germany (“Client”). Selvita’s business cooperation with the Client has begun in 2011. Selvita had reported expansion of its business relationship with the Client in the current stock report no 6/2020 dated March 30th, 2020 and current stock report no 32/2021 dated December 14, 2021.
The subject of the Purchase Order is chemistry support in the FTE model in the Client’s R&D projects leading to the discovery of new drugs over the next 12 months. Supporting the Client’s innovative programs will focus on provision of chemical synthesis services.
Considering the value of the Purchase Order, the Company’s Management Board considers the Purchase Order received to be important for the implementation of Selvita Capital Group’s long-term plans to build a strong position as a leading service provider in the area of supporting drug discovery.
Legal basis: Art. 17.1 MAR
Representatives of the Company:
- Miłosz Gruca – Vicepresident of the Management Board
- Dawid Radziszewski – Member of the Management Board